Milano, 15 giugno 2018

Lung Cancer Session

Highlights

Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona

sara.pilotto@univr.it

• Advisory Boards/Honoraria/Speakers’ fee/Consultant for: – Astra-Zeneca, Eli-Lilly, Boeringher Ingelheim, BMS

• Research Support/Grants from: – A.I.R.C. (Associazione Italiana Ricerca sul Cancro)

– I.A.S.L.C. (International Association for the Study of Lung Cancer)

– Fondazione Cariverona

– Open Innovation

– Astra-Zeneca

Disclosures

Immunotherapy in First Line

KEYNOTE-042

CheckMate-227

[PD-L1<1%]

IMpower150 [OS]

IMpower131

KEYNOTE-407

Steroids

NSCLC

Non-Sq

Sq

Lopes G, ASCO 2018

NSCLC - PD-L1 ≥1% [KEYNOTE-042]

Lopes G, ASCO 2018

OS TPS ≥ 50%

OS TPS ≥ 20%

OS TPS ≥ 1%

Lopes G, ASCO 2018

NSCLC - PD-L1 ≥1% [KEYNOTE-042]

PFS TPS ≥ 50%

PFS TPS ≥ 20%

PFS TPS ≥ 1%

Lopes G, ASCO 2018

Lopes G, ASCO 2018

ORR for TPS 1-49%: pembro 16.6%

versus 21.7% for CT

NSCLC - PD-L1 ≥1% [KEYNOTE-042]

Lopes G, ASCO 2018

NSCLC - PD-L1 ≥1% [KEYNOTE-042]

Any grade thyroiditis (18%) and

pneumonitis (8%)

Lopes G, ASCO 2018

NSCLC - PD-L1 ≥1% [KEYNOTE-042]

NSCLC - PD-L1 < 1% [CHECKMATE-227]

Borghaei H, ASCO 2018

1. Nivo + CT versus CT in patients with PD-L1 < 1% 2. Subset analysis according to TMB status (55%)

Borghaei H, ASCO 2018

NSCLC - PD-L1 < 1% [CHECKMATE-227]

Borghaei H, ASCO 2018

NSCLC - PD-L1 < 1% [CHECKMATE-227]

NSCLC - PD-L1 < 1% [CHECKMATE-227]

Borghaei H, ASCO 2018

NSCLC - PDL1 < 1% [CHECKMATE-227]

Borghaei H, ASCO 2018

Non-Squamous NSCLC [IMpower150]

Socinski M, ASCO 2018

Co-Primary Endpoint Analysis

Non-Squamous NSCLC [IMpower150]

Socinski M, ASCO 2018

Non-Squamous NSCLC [IMpower150]

Socinski M, ASCO 2018

Non-Squamous NSCLC [IMpower150]

Socinski M, ASCO 2018

Non-Squamous NSCLC [IMpower150]

Socinski M, ASCO 2018

Non-Squamous NSCLC [IMpower150]

Socinski M, ASCO 2018

After progression to standard TKI therapyl

Squamous NSCLC [IMpower131]

Jotte R, ASCO 2018

Squamous NSCLC [IMpower131]

Jotte R, ASCO 2018

Squamous NSCLC [IMpower131]

Jotte R, ASCO 2018

HR 1.34 In PD-L1 low (TC1/2 or IC1/2) OS has an

opposite trend

Squamous NSCLC [IMpower131]

Jotte R, ASCO 2018

Squamous NSCLC [IMpower131]

Jotte R, ASCO 2018

Squamous NSCLC [KEYNOTE-407]

Paz-Ares L, ASCO 2018

Squamous NSCLC [KEYNOTE-407]

Paz-Ares L, ASCO 2018

Squamous NSCLC [KEYNOTE-407]

Paz-Ares L, ASCO 2018

Squamous NSCLC [KEYNOTE-407]

Paz-Ares L, ASCO 2018

Squamous NSCLC [KEYNOTE-407]

Paz-Ares L, ASCO 2018

Arbour KC, ASCO 2018

Steroids & Immunotherapy

85% >10mg

Oncogene Addicted

ARCHER 1050 [OS]

NEJ009 [OS]

NEJ026

JO25567 [OS]

ImmunoTarget

Erlotinib + Beva

Mok T, ASCO 2018

Oncogene Addicted [ARCHER 1050]

Mok T, ASCO 2018

Oncogene Addicted [ARCHER 1050]

Mok T, ASCO 2018

Relevant ≥G3 toxicities (diarrhea, paronychia, dermatitis, stomatitis,..)

63% (vs 41%)

Oncogene Addicted [ARCHER 1050]

Oncogene Addicted [ARCHER 1050]

Mok T, ASCO 2018

Oncogene Addicted [NEJ009]

Nakamura A, ASCO 2018

Nakamura A, ASCO 2018

PFS1

PFS2

OS

Oncogene Addicted [NEJ009]

Relevant ≥G3 toxicities (hematological, liver dysfunction,

anorexia, fatigue,..)

Nakamura A, ASCO 2018

Oncogene Addicted [NEJ009]

Nakamura A, ASCO 2018

• 30% vs 19% discontinuation

• 56% vs 37% ≥ G3 toxicities

• 22% HTN and 7% proteinuria G3

Sequist L, ASCO 2018

Oncogene Addicted [NEJ026]

Yamamoto N, ASCO 2018

• 41% discontinuation • 61% HTN and 8%

proteinuria G3

Oncogene Addicted [JO25567]

Oncogene Addicted [ImmunoTarget]

Mazieres J, ASCO 2018

N = 551

Others..

Lymph Node Kit Lung Cancer Screening

Lymph Node Collection Kit for NSCLC

Osarogiagbon RU, ASCO 2018

Over 1,100 resections and 32 surgeons were involved

Lung Cancer Screening

Pham D, ASCO 2018

Lung Cancer Screening

Pham D, ASCO 2018

GRAZIE

PER

L’ATTENZIONE